Literature DB >> 31282073

Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: A systematic review and meta-analysis.

Martina Chiriacò1,2, Konstantinos Pateras3, Agostino Virdis1, Marietta Charakida4, Despoina Kyriakopoulou5, Monica Nannipieri1, Michele Emdin2, Konstantinos Tsioufis5, Stefano Taddei1, Stefano Masi1,4,6, Georgios Georgiopoulos7,8.   

Abstract

AIM: To investigate the associations of blood pressure variability (BPV), expressed as long-term (visit-to-visit) and short-term (ambulatory blood pressure monitoring [ABPM] and home blood pressure monitoring [HBPM]) and all-cause mortality, major adverse cardiovascular events (MACEs), extended MACEs, microvascular complications (MiCs) and hypertension-mediated organ damage (HMOD) in adult patients with type 2 diabetes.
MATERIALS AND METHODS: PubMed, Medline, Embase, Cinahl, Web of Science, ClinicalTrials.gov and grey literature databases were searched for studies including patients with type 2 diabetes, at least one variable of BPV (visit-to-visit, HBPM, ABPM) and evaluation of the incidence of at least one of the following outcomes: all-cause mortality, MACEs, extended MACEs and/or MiCs and/or HMOD. The extracted information was analyzed using random effects meta-analysis and meta-regression.
RESULTS: Data from a total of 377 305 patients were analyzed. Systolic blood pressure (SBP) variability was associated with a significantly increased risk of all-cause mortality (HR 1.12, 95% CI 1.04-1.21), MACEs (HR 1.01, 95% CI 1.04-1.17), extended MACEs (HR 1.07, 95% CI 1.03-1.11) and MiCs (HR 1. 12, 95% CI 1.01-1.24), while diastolic blood pressure was not. Associations were mainly driven from studies on long-term SBP variability. Qualitative analysis showed that BPV was associated with the presence of HMOD expressed as carotid intima-media thickness, pulse wave velocity and left ventricular hypertrophy. Results were independent of mean blood pressure, glycaemic control and serum creatinine levels.
CONCLUSIONS: Our results suggest that BPV might provide additional information rather than mean blood pressure on the risk of cardiovascular disease in patients with type 2 diabetes.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  cardiovascular disease; diabetes complications; macrovascular disease; meta-analysis; systematic review; type 2 diabetes

Year:  2019        PMID: 31282073     DOI: 10.1111/dom.13828

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  20 in total

Review 1.  New Insights into the Role of Visit-to-Visit Glycemic Variability and Blood Pressure Variability in Cardiovascular Disease Risk.

Authors:  Jin J Zhou; Daniel S Nuyujukian; Peter D Reaven
Journal:  Curr Cardiol Rep       Date:  2021-03-02       Impact factor: 2.931

2.  Baseline blood pressure modifies the role of blood pressure variability in mortality: Results from the ACCORD trial.

Authors:  Daniel S Nuyujukian; Michelle S Newell; Jin J Zhou; Juraj Koska; Peter D Reaven
Journal:  Diabetes Obes Metab       Date:  2022-01-24       Impact factor: 6.577

3.  Association between visit-to-visit variability of glycemic indices and lipid profile and the incidence of coronary heart disease in adults with type 2 diabetes.

Authors:  Fatemeh Moosaie; Marjan Mouodi; Ali Sheikhy; Aida Fallahzadeh; Niloofar Deravi; Soghra Rabizadeh; Seyede Marzie Fatemi Abhari; Alipasha Meysamie; Fatemeh Dehghani Firouzabadi; Manouchehr Nakhjavani; Alireza Esteghamati
Journal:  J Diabetes Metab Disord       Date:  2021-11-02

4.  The genetic architecture of blood pressure variability: A genome-wide association study of 9370 participants from UK Biobank.

Authors:  Pingping Jia; Na Zhan; Baker K K Bat; Qi Feng; Kelvin K F Tsoi
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-08-08       Impact factor: 2.885

5.  Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association.

Authors:  Vesna D Garovic; Ralf Dechend; Thomas Easterling; S Ananth Karumanchi; Suzanne McMurtry Baird; Laura A Magee; Sarosh Rana; Jane V Vermunt; Phyllis August
Journal:  Hypertension       Date:  2021-12-15       Impact factor: 9.897

6.  Body Mass Index and Arterial Stiffness Are Associated With Greater Beat-to-Beat Blood Pressure Variability After Transient Ischemic Attack or Minor Stroke.

Authors:  Alastair J S Webb; Amy Lawson; Sara Mazzucco; Linxin Li; Peter M Rothwell
Journal:  Stroke       Date:  2021-02-16       Impact factor: 7.914

7.  Long-Term Variability of Blood Pressure, Cardiovascular Outcomes, and Mortality: The Look AHEAD Study.

Authors:  Arnaud D Kaze; Prasanna Santhanam; Sebhat Erqou; Matthew Yuyun; Alain G Bertoni; Rexford S Ahima; Justin B Echouffo-Tcheugui
Journal:  Am J Hypertens       Date:  2021-08-09       Impact factor: 3.080

8.  Comparison of day-to-day blood pressure variability in hypertensive patients with type 2 diabetes mellitus to those without diabetes: Asia BP@Home Study.

Authors:  Yook-Chin Chia; Kazuomi Kario; Naoko Tomitani; Sungha Park; Jinho Shin; Yuda Turana; Jam Chin Tay; Peera Buranakitjaroen; Chen-Huan Chen; Satoshi Hoshide; Jennifer Nailes; Huynh Van Minh; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Apichard Sukonthasarn; Boon Wee Teo; Narsingh Verma; Yuqing Zhang; Tzung-Dau Wang; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-31       Impact factor: 3.738

9.  Refining determinants of associations of visit-to-visit blood pressure variability with cardiovascular risk: results from the Action to Control Cardiovascular Risk in Diabetes Trial.

Authors:  Daniel S Nuyujukian; Jin J Zhou; Juraj Koska; Peter D Reaven
Journal:  J Hypertens       Date:  2021-11-01       Impact factor: 4.844

10.  Age and sex distribution of beat-to-beat blood pressure variability after transient ischemic attack and minor stroke: A population-based study.

Authors:  Alastair Js Webb; Amy Lawson; Sara Mazzucco; Linxin Li; Peter M Rothwell
Journal:  Int J Stroke       Date:  2020-11-09       Impact factor: 5.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.